Introduction {#s1}
============

Neurons and their axons are produced in excess during mammalian development, followed by a wide-spread culling of excess axons or axonal branches as the nervous system matures. This is exemplified in the development of the peripheral nervous system where sensory axons of the dorsal root ganglion (DRG) compete for limited quantities of target-derived neurotrophins that promote axon survival. Axons that receive sufficient trophic support survive and mature, whereas axons that are insufficiently supported by neurotrophins degenerate ([@bib31]; [@bib45]). Trophic deprivation (TD) triggers the axon to degenerate in three broad steps. Upon TD, the axon first generates a retrograde signal to the neuronal cell body; next, this retrograde signal initiates a pro-degenerative transcriptional response in the cell body; finally, the cell body generates an anterograde signal that propagates to the axon and gates the activation of a latent apoptotic cascade within the axon ([@bib11]; [@bib48]; [@bib33]). A major unanswered question is to define the early signals that induce retrograde signaling to initiate axon degeneration. These upstream pathways represent attractive therapeutic targets to mitigate pathological axon degeneration ([@bib5]; [@bib28]).

It has been shown recently that actin, spectrin and associated molecules form a Membrane-associated Periodic Skeleton (MPS) in axons ([@bib60]), as well as some dendrites ([@bib64]; [@bib7]; [@bib15]), of neurons. The neuronal MPS contains molecules homologous to the components of the erythrocyte membrane skeleton ([@bib3]) but adopts a different ultrastructural organization. In the MPS, actin is arranged into ring-like structures, and these actin rings are connected by heterotetramers of α- and β-spectrin, forming a quasi-one-dimensional (1D) periodic lattice structure underneath the plasma membrane ([@bib60]). The MPS is assembled early during axon development, forming initially in the axonal region proximal to the cell body and then propagating outward to span the entire axonal shaft ([@bib64]). The MPS is also found in dendrites ([@bib64]; [@bib7]) but with lower propensity and developmental rate than in axons ([@bib15]). The MPS is present in all neuronal types examined in the central and peripheral nervous systems ([@bib9]; [@bib16]) and is evolutionally conserved across diverse species ranging from *Caenorhabditis elegans* to *Homo sapiens* ([@bib16]). Genetic perturbations of components of the MPS suggest its importance in processes such as stability and survival of axons under mechanical stress ([@bib13]), touch sensation ([@bib25]), the formation of axon initial segments (AIS) and nodes of Ranvier ([@bib56]; [@bib64]; [@bib8]; [@bib21]), and the maintenance of axon morphology ([@bib29]). The MPS is also found to be important for organizing some membrane proteins, such as ion channels and adhesion molecules ([@bib60]; [@bib64]; [@bib7]; [@bib8]), membrane filtering at the AIS ([@bib1]), and maintenance of axonal microtubules ([@bib41]). Disruption of the MPS causes widespread neurodegeneration and a variety of neurological impairments ([@bib21]; [@bib22]) and has been implicated in neuronal toxicity in Parkinson's disease ([@bib39]).

Understanding the function of the MPS requires observing and altering its behavior and functional organization in the context of specific biological processes. Here, we studied the MPS in the context of sensory axon degeneration. We found that trophic deprivation (TD) induced a rapid disassembly of the MPS, an observation also reported independently ([@bib53]) while our paper was in preparation. Beyond this shared observation, our data further revealed that MPS disassembly occurred early during TD-mediated axon degeneration, prior to detectable caspase activation and protein loss in axons. Importantly, MPS disassembly proceeded even when activation of the apoptotic pathway was blocked, indicating that this structural reorganization is not simply a secondary consequence of TD-dependent proteolysis but may act as a cellular signal early in TD-induced axon degeneration. Furthermore, we showed that acute pharmacological destabilization of actin, which disrupted the MPS, phenocopied TD and generated a pro-degenerative retrograde signal. In contrast, pharmacological stabilization of actin blocked MPS disassembly and prevented TD-induced retrograde signaling. Finally, and surprisingly, genetic knockdown or knockout of βII-spectrin, which inhibits the formation of the MPS ([@bib64]; [@bib15]), prevented retrograde signaling and protected axons from degeneration induced by both TD and actin destabilization. Together, our findings suggest a model that disassembly of the MPS and its associated proteins, which occur early after TD, may play an important role in retrograde signaling during sensory axon degeneration.

Results {#s2}
=======

The MPS is disassembled early upon TD {#s2-1}
-------------------------------------

Sensory axons rely on neurotrophic factors (e.g. nerve growth factor, NGF) for their survival. During TD, multiple pathways converge to drive activation of the intrinsic apoptotic pathway and caspase-dependent cytoskeletal disassembly and axon fragmentation. Genetic deletion of pro-apoptotic proteins Bax, Caspase-9, and Caspase-3 each potently protects axons from degeneration ([@bib47]; [@bib6]; [@bib52]). To promote degeneration, Caspase-3 cleaves a number of key substrates including Calpastatin, an endogenous inhibitor of Calpains. Together, Caspases and Calpains execute axon degeneration by cleaving many proteins including cytoskeleton components ([@bib62]). Caspase activation is thought to be one of the early steps of axon degeneration as it precedes observable signs of degeneration such as blebbing of the plasma membrane and fragmentation of the microtubule network ([@bib44]; [@bib47]). The early Caspase activity can cleave proteins and induce more subtle ultrastructural changes in the axon before larger scale axon fragmentation.

We monitored the structure of the MPS during TD using a super-resolution imaging method, Stochastic Optical Reconstruction Microscopy (STORM) ([@bib42]; [@bib20]). We performed a time course of TD and quantified MPS structural changes by autocorrelation analysis of the 3D STORM images of βII spectrin, a key component of the MPS ([Figure 1](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Axons with a highly periodic MPS organization produce a periodic autocorrelation curve with a high amplitude, and the amplitude decreases as the structure is degraded ([@bib64]; [@bib16]; [@bib15]). Analysis of the MPS in this study was focused on distal axons that were less bundled and exhibited a more regular MPS structure than proximal axons in DRG neurons ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). We initially hypothesized that MPS would be disassembled after Caspases and Calpains are active in the axon, because they cleave protein components of the MPS such as spectrin and actin ([@bib62]). To our surprise, we observed significant disruption of MPS within 6 hr of TD when there was neither obvious axon fragmentation nor detectable increase in immunoreactivity for cleaved (activated) Caspase-3 ([Figure 1](#fig1){ref-type="fig"}).

![MPS disassembly upon TD precedes observable Caspase-3 activation and axon fragmentation.\
Dissociated and re-aggregated wildtype (WT) DRG neurons were cultured for 7 days in the presence of 50 ng/ml NGF and subsequently deprived of NGF (trophic deprivation, TD) for the indicated times. (**A**) Wide-field images of WT axons fixed after a TD time course and stained with antibodies against βII-spectrin (purple) and cleaved (activated) Caspases-3 (green). Scale bar: 20 µm. (**B**) Representative 3D STORM images of βII-spectrin in axonal regions during a TD time course. Scale bar: 1 µm. (**C**) Quantification of the degree of periodicity of βII-spectrin calculated from STORM images, and cleaved Caspase-3 intensity measured by conventional wide-field microscopy. Autocorrelation analysis is applied to each STORM image of βII-spectrin ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) and the autocorrelation amplitude, as defined in [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}, provides a quantification of the degree of periodicity. Axons with highly periodic MPS produce larger autocorrelation amplitude values as compared to axons with lower degree of periodicity. The reported value is the average autocorrelation amplitude derived from many axon regions selected at random, and only a few representative examples are shown in (**B**). Statistics: data are represented as mean ± SEM. Axon number: 19--41 per condition. \*\*p≤0.01. The p value is derived from a two-sided Kolmogorov-Smirnov test. The individual values of MPS autocorrelation amplitudes and cleaved caspase three intensity are listed in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.38730.006Figure 1---source data 1.This spreadsheet contains the values of MPS autocorrelation amplitudes and cleaved Caspase-3 intensity used to generate [Figure 1C](#fig1){ref-type="fig"}.](elife-38730-fig1){#fig1}

The early disassembly of MPS is independent of apoptotic pathway activation and protein loss {#s2-2}
--------------------------------------------------------------------------------------------

We next investigated whether this early MPS disassembly could result from low-level activation of the apoptotic pathway that could not be observed within the detection limits of our assays. We therefore repeated the TD time course in sensory axons that overexpressed the anti-apoptotic protein Bcl-xL. Bcl-xL inhibits Bax, which is in turn required to activate effector Caspases, and it has been shown that the overexpression of Bcl-xL potently blocks axon degeneration following TD ([Figure 2A](#fig2){ref-type="fig"}) ([@bib57]; [@bib48]). Notably, we found that overexpression of Bcl-xL did not inhibit the early disruption of the MPS upon TD ([Figure 2B,C](#fig2){ref-type="fig"}). In parallel, we also measured changes in the MPS in axons from *Bax*-knockout mice ([@bib24]), which are similarly protected from degeneration following TD ([Figure 2A](#fig2){ref-type="fig"}) ([@bib38]; [@bib47]). Consistent with our Bcl-xL overexpression data, MPS disassembly proceeded normally in *Bax*-knockout axons ([Figure 2D,E](#fig2){ref-type="fig"}). Notably, while TD causes a substantial decrease in MPS periodicity, the average fluorescence intensity of βII spectrin in these axon regions was unchanged during the first 12 hr of TD ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), suggesting that the disassembly of the MPS was not a result of the reduced abundance of its protein components during TD. In addition, we repeated a TD time course in parallel cultures and analyzed axon-specific protein lysates by immunoblotting. The overall levels of αII spectrin, βII spectrin and actin in axons remained constant during the first 9 hr of TD when MPS disassembly already started ([Figure 2F](#fig2){ref-type="fig"}), and only at later time points did we observe cleavage of αII spectrin, reflective of a Caspase-dependent cleavage of this protein during TD ([@bib62]). Indeed, this late cleavage of αII spectrin was blocked by expression of Bcl-xL. Together these results indicate that early MPS disassembly upon TD is not a result of activation of the apoptotic pathway or the related degradation of the MPS protein components.

![The disassembly of MPS upon TD is independent of apoptotic pathway activation.\
(**A**) Representative images of 7-day in vitro (DIV) DRG cultures from indicated genotypes and treatments (described as below) following 30 hr TD. Axons are visualized with an antibody to βIII Tubulin (TuJ1). Scale bar: 100 µm. (**B and C**) Dissociated and re-aggregated WT DRG cultures were transduced with lentivirus expressing GFP (B-left panels, C-black curve) or Bcl-xL (B-right panels, C-red curve) one day after plating and deprived of NGF (TD) for varying durations beginning at 8 DIV. Representative 3D STORM images of βII-spectrin in axonal regions in the presence of NGF (top) or at 4 hr of TD (bottom) are shown in (**B**). Scale bar: 1 µm. βII-spectrin autocorrelation amplitude values during the TD time course are quantified in (**C**). Statistics: Data are represented as mean ± SEM. Axon number: 66--104 per condition. \*\*p≤0.01; \*\*\*p≤0.001. p-Values are derived from a two-sided Kolmogorov-Smirnov test. The individual values of MPS autocorrelation amplitudes are listed in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}. (**D and E**) Dissociated and re-aggregated DRG cultures from *Bax* heterozygous (Het, D-left panels, E-black curve) or homozygous knockout (KO, D-right panels, E-red curve) embryos were deprived of NGF (TD) for varying durations starting at 7 DIV. Representative 3D STORM images of βII-spectrin in axonal regions in the presence of NGF (top) or at 3 hr of TD (bottom) are shown in (**D**). Scale bar: 1 µm. Quantification of autocorrelation amplitude values for βII-spectrin during the TD time course is shown in (**E**). Statistics: Data are represented as mean ± SEM. Axon number: 27--53 per condition. \*p≤0.05. p-Values are derived from a two-sided Kolmogorov-Smirnov test. The individual values of MPS autocorrelation amplitudes are listed in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}. (**F**) Protein lysates of isolated axons from 8 DIV DRG cultures expressing the indicated lentiviral constructs (GFP or Bcl-xL) were generated at the indicated time points of TD. Immunoblotting was performed using the indicated antibodies. Red arrows indicate the appearance of degeneration-associated cleavage products of αII spectrin.\
10.7554/eLife.38730.012Figure 2---source data 1.This spreadsheet contains the values of MPS autocorrelation amplitudes used to generate [Figure 2C,E](#fig2){ref-type="fig"}.](elife-38730-fig2){#fig2}

As part of an ongoing, large-scale, unbiased phosphoproteomic screen in axons undergoing TD, we discovered that some protein components of the MPS, including spectrin and adducin, were widely phosphorylated during TD ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, [Figure 2---figure supplement 2---source data 1](#fig2s2sdata1){ref-type="supplementary-material"}). While the full impact of these phosphorylation sites on the MPS components remains to be investigated, analogous phosphorylations on the short C-terminal isoform of βΙΙ spectrin have been previously shown to reduce interactions with αΙΙ spectrin ([@bib4]) and thereby potentially inhibit the formation of the spectrin tetramer. Additionally, analogous phosphorylation on adducin, a protein known to enhance actin-spectrin interaction ([@bib3]), has been found to inhibit formation of spectrin-actin complexes and to affect spectrin localization ([@bib35]; [@bib36]). Therefore, it is possible that the pattern of phosphorylation that we detected on MPS components upon TD may facilitate dissociation of the spectrin-actin-adducin complex and contribute to MPS disassembly.

Pharmacological actin destabilization induces MPS disassembly and pro-degenerative retrograde signals {#s2-3}
-----------------------------------------------------------------------------------------------------

We have previously shown that latrunculin A (LatA), which binds actin monomers and prevents their polymerization, disrupts the MPS in hippocampal neurons ([@bib60]; [@bib64]; [@bib15]). Consistent with our previous results, 3 hr incubation with LatA at a concentration of 20 µM was sufficient to completely disassemble the axonal MPS in DRG sensory neurons and this effect lasted for up to 12 hr after LatA removal ([Figure 3A,B](#fig3){ref-type="fig"}).

![Depolymerization of actin filaments disrupts MPS and induces pro-degenerative signals.\
20 µM of latrunculin A (LatA) or vehicle was applied to relevant DRG cultures (7 DIV) for 3 hr in the presence of NGF. (**A, B**) Representative 3D STORM images of βII-spectrin in axonal regions in untreated (left), LatA-treated (middle), 12-hr recovery (cultured for an extra 12 hr after LatA removal, right) cultures are shown in (**A**) and quantified in (**B**). Scale bar: 1 µm. Statistics: Data are represented as mean ± SEM. Axon number: 27--36 per condition. \*\*\*p≤0.001. p-Values are derived from a two-sided Kolmogorov-Smirnov test. The individual values of MPS autocorrelation amplitudes are listed in [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}. (**C**) 7 DIV DRG cultures were subjected to 6 hr TD or 6 hr treatment with 20 µM LatA, either alone or in the presence of 1 μM DLK inhibitor (DLKi) GNE-3511. Cultures were stained with the DNA dye Hoechst 33342 (blue) and an antibody to phosphorylated c-Jun (Serine 73) (p-c-Jun) (red). Cell bodies are visualized. Scale bar: 50 µm. (**D**) Quantification of the fraction of phosphorylated c-Jun positive cell bodies in (**C**). Data are represented as mean ± SEM. N = 3 independent experiments. \*p≤0.05, \*\*\*p≤0.001, two-way ANOVA with Bonferroni post-test. The individual values of the fraction of phosphorylated c-Jun positive cell bodies are listed in [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}. (**E**) Cultures of WT DRGs were established that expressed lentiviral cytoplasmic NMNAT1. A subset of axons were physically severed from their cell bodies (isolated axons, locate at the lower half of each field of view and are encircled with a dotted red line) while the rest of axons (intact axons, upper left of each field of view) remain connected to cell bodies, followed by either 12 hr TD (left) or 12 hr application of 20 µM LatA. Cultures were stained for cleaved Caspase-3 (top) to indicated Caspase-3 activity and βIII tubulin (TuJ1, bottom) to indicate axons. Scale bar: 100 µm. (**F**) In parallel cultures with (**E**), at 8 DIV, axons were either severed away from their cell bodies ('isolated axons') or left intact ('intact axons') and subjected to 16 hr of TD or 16 hr treatment with 20 μM LatA in the presence of NGF. At the end of the assay (16 hr time point), cell bodies were removed from the 'intact axons,' leaving all cultures with axons but no cell bodies. At the point, axonal DEVDase activity was measured. Data are represented as mean ± SEM. N = 3 independent experiments. \*\*\*p≤0.001, two-way ANOVA with Bonferroni post-test. The individual values of axonal DEVDase activities are listed in [Figure 3---source data 3](#fig3sdata3){ref-type="supplementary-material"}.\
10.7554/eLife.38730.015Figure 3---source data 1.This spreadsheet contains the values of MPS autocorrelation amplitudes used to generate [Figure 3B](#fig3){ref-type="fig"}.\
10.7554/eLife.38730.016Figure 3---source data 2.This spreadsheet contains the values of fraction of p-c-Jun(+) cells used to generate [Figure 3D](#fig3){ref-type="fig"}.\
10.7554/eLife.38730.017Figure 3---source data 3.This spreadsheet contains the values of axonal DEVDase used to generate [Figure 3F](#fig3){ref-type="fig"}.](elife-38730-fig3){#fig3}

We next asked whether the LatA treatment, which causes MPS disassembly, might induce axon degeneration in a manner similar to TD. One of the earliest steps by which TD causes axon degeneration is through the generation of retrograde signals from the axon to the cell body, resulting in phosphorylation and activation of key downstream transcription factors including c-Jun ([@bib11]; [@bib48]). Retrograde signaling functions upstream of caspase activation and depends critically on multiple kinases including the MAPKKK Dual Leucine Zipper Kinase (DLK) ([@bib11]). During TD, DLK activity promotes phosphorylation and activation of c-Jun ([@bib59]; [@bib11]; [@bib23]; [@bib27]). Interestingly, in the context of axon injury, retrograde signaling by activated DLK can also promote axon regeneration ([@bib14]; [@bib61]; [@bib46]; [@bib58]).

Activation of DLK during TD is associated with an increase in its apparent molecular weight on a western blot, reflective of TD-associated phosphorylations ([@bib23]). Similar to the case of TD, we observed an increase in the molecular weight of DLK in axons upon LatA treatment ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In addition, we found that acute application of LatA strongly increased c-Jun phosphorylation and this effect was blocked by co-addition of a small molecule DLK inhibitor, GNE-3511, also similar to the case of TD ([Figure 3C,D](#fig3){ref-type="fig"}). Similar activation of c-Jun in sensory axons has been observed following acute disruption of actin and microtubules with cytochalasin D and nocodazole, respectively ([@bib54]).

It has been shown that retrograde signaling induces a transcriptional response in the cell body and the generation of an anterograde signal from the cell body to the axon that activates a latent pool of Caspase-3 in the axon. Activation of axonal Caspase-3 in turn triggers axon fragmentation ([@bib11]; [@bib48]; [@bib33]). Indeed, physically isolating the axon from its cell body blocks the anterograde signaling and hence the TD-induced axonal Caspase-3 activation ([@bib48]). We therefore examined whether LatA treatment activates axonal Caspase-3, and whether this process, as in the case of TD, requires anterograde signaling from the cell body by severing the axons from their cell bodies immediately prior to LatA treatment. To enable this experiment, we expressed a cytoplasmic variant of the biosynthetic enzyme NMNAT1 (cytoNMNAT1) in wild-type axons, a widely used tool that blocks injury-induced Wallerian degeneration of the axon without interfering with Caspase-3 activation during TD-induced axon degeneration ([@bib43]; [@bib48]). Notably, we found that application of LatA, like TD, induced an increase in cleaved (activated) Caspase-3 in intact axons but not in axons severed from the cell bodies ([Figure 3E](#fig3){ref-type="fig"}). In addition, we also observed an increase in Caspase-3-like enzymatic activity ('DEVDase') in intact axons, but not in isolated axons, in a way similar to TD, although the magnitude of TD-induced axonal DEVDase activity was consistently greater than that elicited by LatA ([Figure 3F](#fig3){ref-type="fig"}). These findings indicate that LatA treatment, like TD, does not directly activate the apoptotic pathway in axons, but instead activates a somatic pro-degenerative pathway that in turn activates axonal Caspase-3 via an anterograde signaling pathway from the cell body.

Pharmacological actin stabilization preserves MPS during TD and inhibits pro-degenerative retrograde signals {#s2-4}
------------------------------------------------------------------------------------------------------------

Next, we asked whether stabilizing F-actin had the opposite effect on TD-induced MPS disassembly and retrograde signaling. We used Jasplakinolide (Jasp), a toxin that promotes actin polymerization and thereby stabilizes F-actin. We note that the addition of Jasp occasionally caused depletion of the MPS in a fraction of axonal segments, but the majority of axonal regions exhibited intact MPS ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). We repeated a time course of TD in the presence of Jasp and found that Jasp effectively prevented disassembly of the MPS upon TD ([Figure 4A,B](#fig4){ref-type="fig"}). This observation is consistent with the independent finding that actin stabilization can inhibit MPS disassembly and axon fragmentation ([@bib53]), but TD-induced retrograding signaling has not been studied in [@bib53]. To examine the effect of Jasp treatment on TD-induced retrograde signaling in axon degeneration, we examined phosphorylation of c-Jun and found that application of Jasp prevented the TD-induced rise in phosphorylated c-Jun (p-c-Jun) ([Figure 4C,D](#fig4){ref-type="fig"}), which is required in part for TD-induced degeneration ([@bib48]). Likewise, Jasp treatment prevented the TD-induced increase in the molecular weight of axonal DLK ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), a proxy for DLK activation ([@bib23]). Interestingly, application of Jasp alone caused a small rise in the amount of detectable phosphorylated c-Jun-positive cells ([Figure 4C,D](#fig4){ref-type="fig"}), perhaps reflecting a low-level stress response initiated by inhibition of normal actin turnover.

![Stabilizing actin filaments preserves MPS and blocks pro-degenerative retrograde signals.\
WT DRG cultures (7 DIV) were pretreated with 10 µM Jasplakinolide (Jasp) or vehicle for 30 min, followed by a TD time course in the continued presence of Jasp. (**A**) Representative 3D STORM images of βII-spectrin in axonal regions in cultures without (left) or with (right) Jasp treatment in the presence of NGF (top) or at 12 hr of TD (bottom). Scale bar: 1 µm. (**B**) Autocorrelation amplitude values for βII-spectrin in cultures without (black) or with (red) application of Jasp. Statistics: Data are represented as mean ± SEM. Axon number: 39--61 per condition. \*\*\*p≤0.001; n.s. p\>0.05. p-Values are derived from a two-sided Kolmogorov-Smirnov test. The individual values of MPS autocorrelation amplitudes are listed in [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}. (**C**) Immunoreactivity for phosphorylated c-Jun (p-c-Jun) in 7 DIV DRG cultures in the presence of NGF or following an 8 hr TD, without or with 1 µM Jasp pre-incubation for 30 min prior to the assay, as indicated. Scale bar: 50 µm. (**D**) Quantification of the fraction of phosphorylated c-Jun positive cell bodies. Statistics: Data are represented as mean ± SEM. N = 3 independent experiments,\~400 cell neurons per assay. \*\*\*p≤0.001. The individual values of the fraction of phosphorylated c-Jun positive cell bodies are listed in [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}.\
10.7554/eLife.38730.022Figure 4---source data 1.This spreadsheet contains the values of MPS autocorrelation amplitudes used to generate [Figure 4B](#fig4){ref-type="fig"}.\
10.7554/eLife.38730.023Figure 4---source data 2.This spreadsheet contains the values of fraction of p-c-Jun(+) cells used to generate [Figure 4D](#fig4){ref-type="fig"}.](elife-38730-fig4){#fig4}

Together, our observations of the early caspase-independent MPS disassembly upon TD and of the correlation between the bi-directional modulation of MPS stability and retrograde signaling in axon degeneration suggest a potential signaling role for this axonal membrane skeleton in the initiation of axon degeneration.

Depletion of the MPS component βII spectrin protects axons from degeneration {#s2-5}
----------------------------------------------------------------------------

Next, we investigated the effect of depletion of βII spectrin, a key component of the MPS, on TD-induced axon degeneration. To achieve this, we transfected DRG neurons with a validated adenovirus (AV)-based shRNA to βII spectrin (*Sptbn1*) ([@bib10]; [@bib64]; [@bib15]) and observed nearly complete removal of βII spectrin at the time of our assay ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Axons derived from these cultures displayed a down-regulation of some additional MPS components (αII spectrin and ankyrin-B), perhaps reflective of a stabilizing effect of the MPS against the degradation of some of its components, though βII spectrin depletion caused no change in the abundance of actin and βIII tubulin ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Remarkably, we found that knockdown of βII spectrin strongly protected axons from TD-induced degeneration ([Figure 5A,B](#fig5){ref-type="fig"}). TD is known to induce a rise in Caspase-3-like enzymatic activity ('DEVD-ase') in axons ([@bib48]), and we found that βII spectrin knockdown also blocked this rise in 'DEVD-ase' activity upon TD ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). To further validate this finding, we established cultures from βII spectrin conditional knockout mice and infected these cultured neurons with Cre recombinase via lentiviral constructs to achieve a comparable removal of βII spectrin. Consistent with our shRNA knockdown results, genetic deletion of βII spectrin also protected axons from degeneration following TD ([Figure 5C,D](#fig5){ref-type="fig"}). In contrast to the protection observed against TD, loss of βII spectrin offered no appreciable protection against axon degeneration caused by direct activation of the apoptotic pathway (by the Bcl-2/Bcl-xL/Bcl-w antagonist ABT-737), or direct damage to the mitochondria (by rotenone) or to the microtubule cytoskeleton (by vincristine) ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). We next examined activation of c-Jun and Foxo3a in wild type and βII-spectrin-deficient axons undergoing TD. We found that βII-spectrin knockdown inhibited the TD-induced rise in c-Jun mRNA ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}), and prevented the increase in phosphorylated c-Jun ([Figure 5E,F](#fig5){ref-type="fig"}) and nuclear-localized Foxo3a ([Figure 5G,H](#fig5){ref-type="fig"}) upon TD, which are early events during axon degeneration signaling ([@bib11]; [@bib33]; [@bib48]). Interestingly, the TD-induced activation of DLK, an earlier step in pro-degenerative retrograde signaling was unaffected in βII-spectrin knockdown cultures ([Figure 5I](#fig5){ref-type="fig"}). These results suggest that the protection against axon degeneration offered by βII-spectrin removal occurs early in the degeneration pathway, upstream of axonal apoptotic pathway activation and the activation of transcription factors c-Jun and Foxo3a, but downstream of DLK phosphorylation/activation.

![Depletion of the MPS component βII spectrin inhibits retrograde signaling and protects axons from degeneration.\
(**A, B**) Dissociated and re-aggregated WT DRG cultures were infected with AV-shRNA against βII-spectrin (*Sptbn1*) or scrambled control at 1 DIV and deprived of NGF (TD) for the indicated time points starting at 8 DIV. Axons are visualized with βIII tubulin (TuJ1) immunostaining in (**A**) and degenerated axons are quantified over time in (**B**). Scale bar: 100 µm. Statistics: n = 4 independent experiments. \*p≤0.05, \*\*\*p≤0.001, two-way ANOVA with Bonferroni post-test. The individual values of ratio of axons degenerated are listed in [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}. (**C, D**) Dissociated and re-aggregated DRG cultures from the indicated genotype were transduced with lentivirus expressing GFP as a control or lentivirus expressing Cre recombinase to delete the βII-spectrin (*Sptbn1*) gene from 1 DIV. The cultures were deprived of NGF (TD) for the indicated time points starting at 8 DIV. Axon degeneration was visualized in (**C**) and quantified over time in (**D**). Scale bar: 100 µm. Statistics: Data are represented as mean ± SEM. n = 3 independent experiments. \*\*\*p≤0.001, two-way ANOVA with Bonferroni post-test. The individual values of ratio of axons degenerated are listed in [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}. (**E**) DRG cultures expressing AV-based scrambled shRNA or shRNA against βII-spectrin were subjected to 6 hr TD and stained with an antibody to phosphorylated c-Jun (p-c-Jun). Scale bar: 50 µm. (**F**) Quantification of the fraction of cells immunoreactive for p-c-Jun from (**E**). Data are represented as mean ± SEM. n = 3 independent experiments. \*\*\*p≤0.001, two-way ANOVA with Bonferroni post-test. The individual values of the fraction of phosphorylated c-Jun-positive cell bodies are listed in [Figure 5---source data 3](#fig5sdata3){ref-type="supplementary-material"}. (**G**) As in (**E**) but for cultures stained with antibody to Foxo3a. Nuclear import of Foxo3a is visualized by co-localization with the DNA dye Hoechst 33342. (**H**) Quantification of the fraction of cells from (**G**) where Foxo3a immunoreactivity appears to co-localize with Hoechst 33342 staining. Data are represented as mean ± SEM. n = 3 independent experiments. \*\*\*p≤0.001, two-way ANOVA with Bonferroni post-test. The individual values of the fraction of cells with nuclear Foxo3a are listed in [Figure 5---source data 4](#fig5sdata4){ref-type="supplementary-material"}. (**I**) Cultures were infected at 1 DIV with AVs expressing scrambled shRNA or shRNA against βII spectrin (*Sptbn1*). At 8 DIV, cultures were subjected to TD (12 hr), followed by removal of cell bodies and axon-specific lysis. Samples were subjected to immunoblotting as indicated. The TD-associated shift in DLK molecular weight was visualized using a phos-Tag gel (see Materials and methods). Representative western blot from three independent biological replicates.\
10.7554/eLife.38730.032Figure 5---source data 1.This spreadsheet contains the values of fraction of axons degenerated used to generate [Figure 5B](#fig5){ref-type="fig"}.\
10.7554/eLife.38730.033Figure 5---source data 2.This spreadsheet contains the values of fraction of axons degenerated used to generate [Figure 5D](#fig5){ref-type="fig"}.\
10.7554/eLife.38730.034Figure 5---source data 3.This spreadsheet contains the values of fraction of p-c-Jun(+) cells used to generate [Figure 5F](#fig5){ref-type="fig"}.\
10.7554/eLife.38730.035Figure 5---source data 4.This spreadsheet contains the values of fraction of cells with nuclear Foxo3a used to generate [Figure 5H](#fig5){ref-type="fig"}.](elife-38730-fig5){#fig5}

To examine a role for βII spectrin in pro-degenerative retrograde signaling more broadly, we applied LatA to βII-spectrin knockdown cultures and observed that loss of βII spectrin prevents the LatA-induced appearance of axonal DEVDase activity ([Figure 5---figure supplement 3A](#fig5s3){ref-type="fig"}), although interestingly not the LatA-induced rise in phospho-c-Jun ([Figure 5---figure supplement 3B,C](#fig5s3){ref-type="fig"}). This is likely because LatA treatment, which disrupts all forms of F-actin, initiates an additional, less specific and βII-spectrin-independent signal to activate c-Jun, although this signal does not appear to lead to axon degeneration.

Discussion {#s3}
==========

The axonal MPS is a plastic structure that disassembles early during axon degeneration and independently of the apoptotic pathway {#s3-1}
---------------------------------------------------------------------------------------------------------------------------------

The membrane skeleton structure MPS, comprised of actin, spectrin and associated molecules, is assembled early during axon development and remains a stable structure in mature, unstimulated neurons ([@bib64]). Here, we report data that suggest a novel plasticity in the MPS upon trophic deprivation (TD).

We show that removal of neurotrophic support causes a rapid disassembly of the MPS structure. A similar observation has been reported independently ([@bib53]) while our paper was in preparation, but ([@bib53]) did not investigate the relationship of MPS disassembly to either the Caspase-dependent apoptotic pathway or the retrograde signaling induced by TD. Several MPS components are themselves Caspase substrates, and we and others have observed low-level Caspase activation that precedes apparent signs of axon fragmentation ([@bib44]; [@bib47]), thus the MPS disassembly could potentially be a simple consequence of the activation of the axonal apoptotic pathway during axon degeneration. However, unexpectedly, we find that MPS disassembly occurs without a change in the abundance of its component proteins. Additionally, the disassembly still proceeds normally in axons deficient in apoptotic pathway activation, suggesting that the disassembly happens upstream of Caspase-dependent proteolysis. Together these findings indicate that MPS disassembly is an early event in the TD-induced degeneration pathway, independent of Caspase-dependent proteolysis.

We also observe extensive TD-induced phosphorylation on MPS components, spectrin and adducin. Increased phosphorylation of β spectrin has been reported to decrease membrane mechanical stability in erythrocytes ([@bib32]). In addition, analogous phosphorylation on a βΙΙ-spectrin isoform reduces its interaction with αΙΙ spectrin ([@bib4]) and analogous phosphorylation on adducin inhibits formation of the spectrin-actin complex ([@bib35]; [@bib36]). While the biological significance of TD-induced phosphorylation on spectrin and adducin in axons remains to be determined, it is possible that these phosphorylation events could potentially facilitate MPS disassembly by affecting the stability of the actin-spectrin complex. Furthermore, MPS disassembly upon TD is prevented by pharmacologically stabilizing F-actin, suggesting that TD-induced activation may activate one or more actin modifying enzymes, which may in turn contribute to driving the observed MPS structural changes.

Depletion of βII-spectrin inhibits retrograde signaling and protects axons from degeneration {#s3-2}
--------------------------------------------------------------------------------------------

Loss or mutation of α/β spectrin family members from birth has profound consequences on nervous system development and integrity from *C. elegans* through mammals ([@bib49]; [@bib40]; [@bib13]; [@bib56]; [@bib63]; [@bib25]; [@bib26]; [@bib21]; [@bib22]). Because of the known importance of spectrin in development, to investigate its role in axon degeneration by genetic manipulation, we removed βII spectrin from established neuronal cultures using virally delivered shRNA or Cre recombinase. Our data uncover a novel post-developmental role for βII spectrin that is required for axon degeneration at an early step, likely through the regulation of retrograde signaling. We observed that the depletion of βII spectrin protects axons from degeneration following TD, and that this effect is downstream of the activation of DLK but upstream of c-Jun activation. In addition, loss of βII spectrin also inhibits the pro-degenerative effects of acute F-actin breakdown by the actin depolymerization drug LatA. It has been shown previously that beta-II spectrin depletion disrupts the MPS in cultured hippocampal neurons based on actin and adducin imaging ([@bib64]; [@bib15]). Because the longitudinal actin filaments mask the periodic structure more strongly and that adducin signal is relatively weak in distal axonal regions in DRG neurons, it is challenging to use these markers to assess MPS integrity in DRG neurons. However, we observed that beta-II spectrin knockdown led to substantial decrease in the abundance of some other MPS components, such as alpha-II spectrin and ankyrin-B, suggesting that the MPS is likely also disrupted in beta-II spectrin depleted DRG neurons.

Our data suggest that βII spectrin functions, possibly in the context of the MPS, as a novel factor in TD-induced retrograde signaling and axon degeneration. Precisely how βII spectrin is involved in retrograde signaling in the axon remains to be determined. TD-induced retrograde signaling involves at least two pathways in sensory axons. The first is loss of pro-survival Akt activity, culminating in activation of the downstream transcription factor Foxo3a ([@bib48]). The second is a gain of pro-degenerative MAPK signaling, mediated by DLK, and culminating in phosphorylation and activation of the transcription factor c-Jun ([@bib11]; [@bib23]; [@bib48]). In neurons lacking DLK, phosphorylation of c-Jun is blocked and activation of Foxo3a is strongly attenuated ([@bib11]; [@bib48]), suggesting a crosstalk between these two pathways. Loss of βII spectrin does not block DLK activation following TD, but largely blocks phosphorylation of c-Jun and nuclear translocation of Foxo3a, suggesting that βII spectrin is potentially involved in both pathways, but the extent to which βII spectrin interacts with each remains to be determined.

Structural plasticity of the MPS potentially functions to initiate retrograde signaling {#s3-3}
---------------------------------------------------------------------------------------

Our data show that actin stabilization by Jasp prevents MPS disassembly and occludes the somatic response to TD (i.e. inhibits activation of DLK and c-Jun), suggesting that F-actin turnover is critical to this early phase of axon degeneration. Conversely, acutely destabilizing actin with LatA largely phenocopies TD, inducing MPS disassembly and promoting retrograde signaling (i.e. activation of DLK and c-Jun), culminating in activation of the somatic pro-degenerative program. βII spectrin depletion blocks the pro-degenerative effects of LatA-induced acute F-actin breakdown. Together with the observed early disassembly of MPS upon TD and the protection against TD-induced degeneration by βII spectrin depletion, these data suggest a possibility that structural plasticity of the MPS is important for pro-degenerative retrograde signaling.

The MPS lacks a net polarity toward the distal axon or cell body, so it is unlikely to act as a 'track' for pro-degenerative retrograde signal propagation. Instead, the MPS structure may possibly serve as a platform to coordinate the activation of this retrograde signal. The sub-membrane lattice structure of the MPS provides a mechanism for anchoring transmembrane proteins, likely in a way similar to the erythrocyte membrane skeleton ([@bib18]; [@bib3]; [@bib2]). Indeed, some functional membrane proteins are organized into periodic distributions along the axons by the MPS ([@bib60]; [@bib64]; [@bib7]; [@bib8]). It is thus possible that the MPS sequesters and thus functionally inactivates some pro-degenerative signaling molecules in healthy axons to prevent aberrant signaling, but also primes axons for degeneration by recruiting these molecules to the appropriate region of the axons. MPS disassembly might then activate retrograde signaling by releasing these signaling molecules. On the other hand, inhibiting establishment of the MPS may lead to mislocalization of these signaling molecules, resulting in failure of retrograde signaling. This model could explain why stabilization of the MPS (with Jasplakinolide) or inhibition of its formation (with knockdown/knockout of βII spectrin) both blocks pro-degenerative retrograde signaling and axon degeneration, while MPS disassembly (by TD or LatA treatment), can promote retrograde signaling and axon degeneration. Another possibility is that MPS breakdown during TD (or following LatA treatment) produces a pool of soluble MPS components, such as spectrin and ankyrin, which could participate in retrograde trafficking. Of note, biochemical reconstitution of dynein-driven retrograde signaling in the axon has demonstrated a prominent role for PH domain-containing β spectrins, including βΙΙ spectrin, in bridging vesicular membranes to dynein-driven retrograde motors ([@bib37]). In addition, AnkB, which is associated with the MPS, has been shown as a motor protein adaptor important for retrograde transport of multiple organelles, such as endosomes and mitochondria, in hippocampal neurons ([@bib30]). The disassembly of the MPS to free these MPS components could promote the role of these proteins in retrograde transport, which might in turn facilitate retrograde signaling in TD-induced axon degeneration.

Finally, we note that it is difficult to disentangle the roles of different cytoskeleton structures due to their interactions and due to the fact that pharmacological and genetic manipulations often perturb multiple cytoskeletons simultaneously and may induce transcriptional responses ([@bib34]). Therefore, while acute manipulations that modify F-actin by LatA and Jasp have clear effects on the MPS, we cannot exclude the possibility that the observed effects of pharmacological manipulations on the initiation of axon degeneration occur through other actin structures. Similarly, the depletion of βΙΙ spectrin could also affect microtubule structure and microtubule-dependent retrograde transport in addition to the structure of the MPS ([@bib41]). Accordingly, while our manipulations of F-actin and βΙΙ spectrin converge on the MPS, it is also possible that other cytoskeleton structures may contribute to the observed effects on axon degeneration.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\              Designation                                                                      Source or\                Identifiers                                                                        Additional\
  or resource                                                                                                           reference                                                                                                    information
  ------------------------------------ -------------------------------------------------------------------------------- ------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------
  Genetic reagent (*M. musculus*)      Sptbn1-flox                                                                      [@bib10]                  RRID:[MGI:5431637](https://scicrunch.org/resolver/MGI:5431637)                     Dr. Matt Rasband (Baylor College of Medicine)

  Genetic reagent (*M. musculus*)      Bax KO                                                                           [@bib24]                  RRID:[MGI:1857429](https://scicrunch.org/resolver/MGI:1857429)                     Dr. Stanley Korsmeyer (via Jackson Labortory)

  Antibody                             mouse monoclonal anti-βII spectrin, clone 42                                     Santa Cruz                Cat. \# sc-136074; RRID:[AB_2194501](https://scicrunch.org/resolver/AB_2194501)    IF (1:100), WB (1:500)

  Antibody                             rabbit anti-Tubulin β 3                                                          BioLegend                 Cat. \# 845502; RRID:[AB_2566589](https://scicrunch.org/resolver/AB_2566589)       IF (1:2000)

  Antibody                             mouse monoclonal anti-Tubulin β 3                                                BioLegend                 Cat. \# MMS-435P; RRID:[AB_2313773](https://scicrunch.org/resolver/AB_2313773)     IF (1:2000), WB (1:1000)

  Antibody                             rabbit anti-cleaved Caspase-3                                                    Cell Signaling            Cat. \# 9661; RRID:[AB_2341188](https://scicrunch.org/resolver/AB_2341188)         IF (1:100)

  Antibody                             rabbit monoclonal anti-cleaved Caspase-3                                         Cell Signaling            Cat. \# 9664; RRID: [AB_2070042](https://scicrunch.org/resolver/AB_2070042)        IF (1:100)

  Antibody                             Rabbit monoclonal anti-phosphorylated c-Jun S73                                  Cell Signaling            Cat. \# 3270; RRID: [AB_2129575](https://scicrunch.org/resolver/AB_2129575)        IF (1:500)

  Antibody                             rabbit anti-Foxo3a                                                               Cell Signaling            Cat. \# 12829; RRID: [AB_2636990](https://scicrunch.org/resolver/AB_2636990)       IF (1:200)

  Antibody                             rabbit polyclonal anti-DLK                                                       Genetex                   Cat. \# GTX124127                                                                  WB (1:500)

  Antibody                             mouse anti-αII spectrin                                                          BioLegend                 Cat. \# 803201; RRID: [AB_2564660](https://scicrunch.org/resolver/AB_2564660)      WB (1:250)

  Antibody                             rabbit anti-α-adducin                                                            Abcam                     Cat. \# ab51130; RRID: [AB_867519](https://scicrunch.org/resolver/AB_867519)       WB (1:100)

  Antibody                             mouse anti-Ankyrin B                                                             Neuromab                  Cat. \# 75--145; RRID: [AB_10673095](https://scicrunch.org/resolver/AB_10673095)   WB (1:100)

  Antibody                             rabbit monoclonal anti-β actin                                                   Revmab                    Cat. \# 31-1013-00; RRID:[AB_2716368](https://scicrunch.org/resolver/AB_2716368)   WB (1:3000)

  Chemical compound, drug              Hoechst 33342                                                                    ThermoFisher Scientific   Cat. \# H3570                                                                      IF (1:10,000)

  Chemical compound, drug              Jasplakinolide                                                                   Millipore Sigma           Cat. \# 420107 M                                                                   Drugs were pre-dissolved in culture medium (sonicate shortly if necessary) for MPS imaging and in DMSO for other assays.

  Chemical compound, drug              Jasplakinolide                                                                   Abcam                     Cat. \# 141409                                                                     

  Chemical compound, drug              Latrunculin A                                                                    Millipore Sigma           Cat. \# L5163                                                                      

  Chemical compound, drug              Latrunculin A                                                                    Abcam                     Cat. \# 144290                                                                     

  Chemical compound, drug              GNE-3511                                                                         Millipore Sigma           Cat. \# 533168                                                                     

  Chemical compound, drug              ABT-737                                                                          Selleck Chem              Cat. \# S1002                                                                      

  Commercial assay, kit                Caspase-Glo 3/7 reagent                                                          Promega                   Cat. \# G8090                                                                      

  Transfected construct (adenovirus)   βII-spectrin silencing, Gift from Baylor College of Medicine (Matthew Rasband)   [@bib10]                                                                                                     

  Transfected construct (adenovirus)   Scrambled shRNA with GFP                                                         Vector Biolabs            Cat. \# 1122                                                                       

  Transfected construct (lentivirus)   Lentivirus expressing mouse Bcl-xL cDNA                                          [@bib48]                                                                                                     

  Transfected construct (lentivirus)   Lentivirus expressing GFP DNA                                                    [@bib48]                                                                                                     

  Transfected construct (lentivirus)   Lentivirus expressing Cre recombinase                                            [@bib48]                                                                                                     

  Transfected construct (lentivirus)   Lentivirus expressing cytoplasmic NMNAT1 cDNA                                    [@bib48]                                                                                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

Animals were bred and used according to IACUC protocols at The Rockefeller University and Stanford University. Embryos were harvested from pregnant dams at stage E12.5 where the plug date is standardized as E0.5. Wild-type cultures were generated from CD1 mice (Charles River). For mutant strains, comparisons between wild-type and mutant used tissues derived from the embryos from a single pregnant female. *Bax* knockout mice ([@bib24]) were purchased from Jackson Labs. *Sptbn1* conditional knockout mice ([@bib63]) were a kind gift from Dr. Matthew Rasband (Baylor College of Medicine).

Neuronal cultures {#s4-2}
-----------------

Sensory neuron cultures were established as previously described ([@bib48]). Briefly, E12.5 DRGs were isolated from spinal cords and dissociated in 0.05% Trypsin-EDTA (Life Technologies) for 20 min, washed once in DMEM media containing 10% FBS, then resuspended in culture media: Neurobasal (Life Technologies) containing 2% (v/v) B27 (Life Technologies), 0.45% (v/v) Glucose, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and supplemented with 50 ng/mL NGF (Promega). Cells were plated on dried substrate in multi-well chamber slides at a density of \~15,000 per 1--1.5 microliters, allowed to adhere in a humidified incubator for \~12--15 min, at which time the chambers were filled with media and cultures returned to the incubator. The plating configuration allows for radial axon outgrowth away from a pool of cell bodies located near the center of the well. For imaging proximal axons, we used dissociated cells uniformly plated at a reduced density of \~4000 per well to avoid axon bundling. Cells were treated with mitotic inhibitor (5 µM 5-fluorouracil and 5 µM uridine) the morning after plating. For experiments involving STORM imaging, E12.5 DRGs were dissected away from embryonic spinal cords and shipped overnight from either Rockefeller or Stanford to Harvard in Hibernate-E media (Life Technologies) supplemented with 2% (v/v) B27. Upon arrival the DRGs were dissociated and plated as above. All assays were performed at 7--8 days in vitro (DIV). In cases where viral manipulation was used, cultures were infected with virus at 1 DIV and assayed at 8 DIV. Trophic deprivations were performed by replacing NGF-containing culture media with media containing no NGF as well as a function-blocking antibody to NGF. For STORM imaging experiments, cultures were plated on poly-D-lysine (40 µg/ml), and then N-cadherin (1 µg/ml, R and D systems) and fibronectin (5 µg/ml, R and D systems). All other cultures were plated on poly-D-lysine (100 µg/ml) and mouse natural laminin (10 µg/ml, Life Technologies).

Viral production {#s4-3}
----------------

Lentiviruses encoding GFP, Cre Recombinase, and cytoplasmic NMNAT1 were produced and used as previously described ([@bib48]). AV-shRNA against βII spectrin was a kind gift from Dr. Matthew Rasband (Baylor College of Medicine) as described previously ([@bib17]; [@bib10]; [@bib64]). An AV- scrambled shRNA was used as a control (Vector Biolabs \#1122).

Western blotting {#s4-4}
----------------

Protein abundance was determined by western blotting using standard techniques as previously described ([@bib48]). For axon-specific lysates, cell bodies at the center of the well (spotted as described above) were removed with a scalpel and axons were lysed directly in the well in a buffer containing 50 mM Tris-HCl (pH 6.8), 8M Urea, 10% (w/v) SDS, 10 mM sodium EDTA, 50 mM DTT, supplemented with Brilliant Blue G. For each condition examined, axons harvested from at least eight spot cultures (15,000 neurons per spot) were pooled. Samples were resolved on 4--15% pre-cast protein gels (Bio-Rad \#3450029) in all cases except for visualizing the molecular weight shift of DLK, for which a pre-cast 7.5% Super-Sep Phos-tag polyacrylamide gel (Wako, \#198--17981) was used.

Measurement of axonal DEVDase activity {#s4-5}
--------------------------------------

Dissociated and re-aggregated sensory neuron spot cultures, prepared as described above, were grown in 24-well plastic cell culture plates and treated as indicated (TD, LatA, etc.). At the terminal time point in the assay, cell bodies were removed using a scalpel (identical to parallel cultures used for protein harvesting). Next, half the culture media was removed, followed by addition of an equal volume of Caspase-Glo 3/7 reagent (Promega \#G810C). Following a one-hour lysis at room temperature with gentle rocking, the contents of each well was transferred to an opaque 96-well plate and luminescence was determined using a plate reader. A minimum of four independent spots were measured for each assay condition.

cDNA production and Real-Time PCR measurements {#s4-6}
----------------------------------------------

Total RNA from eight spot cultures per condition was collected using the RNeasy Micro Kit (Qiagen \# 74104). cDNA was generated using Superscript III (ThermoFisher \#18-080-051) from a defined amount of total RNA (normalized across experimental conditions), followed by real-time PCR experiments using the Taqman Gene Expression system (ThermoFisher \# 4369016). Pre-designed primer pairs were used for c-Jun (ThermoFisher \#Mm00495062_s1) and GAPDH (ThermoFisher \#Mm99999915_g1).

Immunofluorescence and imaging {#s4-7}
------------------------------

Cultures for visualization of c-Jun and Foxo3a were fixed in 4% paraformaldehyde and 10% sucrose in PBS for 15 min at room temperature. Following one wash in PBS the cultures were blocked in 6% donkey serum in PBS containing 0.1% Triton X-100 (PBS-X) for 3 hr, and incubated in primary antibody in 3% donkey serum in PBS-X, overnight at room temperature. The next morning, following three 10 min washes in PBS-X, AlexaFluor-conjugated secondary antibodies were added (1:500) in 3% donkey serum in PBS-X for 1 hr at room temperature. Following two 10-min washes in PBS-X, a final wash containing 1:1000 Hoechst dye in PBS-X was performed. Slides were mounted in Fluoromount-G (Southern Biotech) and imaged on a Nikon Eclipse upright microscope.

Cultures for STORM imaging and visualization of other MPS associated proteins were fixed at various DIV as indicated in the main text, at a final concentration of 4% (wt/vol) paraformaldehyde by adding equal volume of fixation buffer (8% wt/vol paraformaldehyde and 4% wt/vol sucrose in 1 × PBS) to cell culture medium. Neurons were fixed for 25 min, wash three times with 1 × PBS, permeabilized with 0.05% (vol/vol) Triton X-100 in 1 × PBS for 5 min, blocked in blocking buffer (3% wt/vol BSA in 1 × PBS) for 50 min at room temperature and subsequently stained with either primary antibodies against βII spectrin and neuron-specific Class III β-tubulin (TuJ1) in blocking buffer for \~15 hr at 4°C. The samples were washed three times with 1 × PBS for 10 min each and then stained with secondary antibodies (Alexa Fluor 647 donkey anti-mouse, Invitrogen, A31571; Alexa Fluor 555 goat anti-rabbit, Invitrogen, A21428) in blocking buffer for 50 min -- 1 hr at room temperature. The samples were then washed three times with 1 × PBS for 10 min each, fixed again with 4% (wt/vol) paraformaldehyde in 1 × PBS for 15 min, washed three times with 1 × PBS and stored in 1 × PBS before imaging.

The STORM setup was based on an Olympus IX-71 inverted optical microscope as described previously ([@bib20]; [@bib42]). A 405 nm (Coherent CUBE 405--50C) laser beam, a 560 nm (Coherent Sapphire) laser beam and a 640 nm (Coherent Genesis MX) laser beam were introduced into the sample through the back port of the microscope. A translation stage allowed the laser beams to be shifted toward the edge of the objective so that the emerging light reached the sample at incidence angles slightly smaller than the critical angle of the glass-water interface, thus illuminating only the fluorophores within a few micrometers of the coverslip surface. A T660LPXR (Chroma) dichroic mirror and an ET705/72M band-pass emission filter (Chroma) were used for imaging of Alexa Fluor 647; a Di01-561 (Semrock) dichroic mirror and an FF01-617/73 band-pass emission filter (Semrock) were used for imaging Alexa Fluor 555. For 3D STORM imaging, a cylindrical lens was inserted into the imaging path so that images of single molecules were elongated in *x* and *y* for molecules on the proximal and distal sides of the focal plane (relative to the objective), respectively ([@bib20]).

The sample was imaged in an air-tight container filled with \~2.5 ml image buffer per well in a four-well chamber (10% (wt/vol) glucose, 50 mM Tris-HCl pH 7.5, additional 10 mM NaCl, 10 mM cysteamine, 1 mg/mL glucose oxidase (Sigma-Aldrich), and 40 μg/mL catalase (Roche Applied Science) in 1 × PBS).

Axons were selected based on TuJ1 staining (wide-field conventional image with 561 nm laser) to achieve a blind selection of regions for STORM imaging of βII spectrin and according to the criteria that they should be at between \~3 mm away from the cell body aggregation in the middle of the well to \~40 µm from the tip of an axon. Only unbundled axons with a diameter less than 700 nm were selected.

During STORM imaging, continuous illumination of 640 nm laser (∼2 kW/cm2) was used to excite fluorescence from Alexa Flour 647 molecules and switched them into the dark state. Continuous illumination of the 405 nm laser was used to reactivate the fluorophores to the emitting state. The power of the activation lasers was adjusted during image acquisition so that, at any given instant, fluorophores in the emitting state were mostly non-overlapping with each other.

A typical STORM image was generated from a sequence of 25,000 image frames at a frame rate of 60 Hz. The recorded STORM movie was analyzed according to previously described methods ([@bib20]; [@bib42]). The centroid positions and ellipticities of the single-molecule images provided lateral and axial positions of each activated fluorescent molecule, respectively. Super-resolution images were reconstructed from the molecular coordinates by depicting each location as a 2D Gaussian peak.

Quantification of STORM images {#s4-8}
------------------------------

Autocorrelation analyses were performed on the molecule list of selected imaging areas similar to what has been described previously ([@bib64]; [@bib16]; [@bib15]). Briefly, 1-D single-molecule localization distribution of an axon was first computed using a bin size of 10 nm. Then the distribution was segmented into several 1900 nm adjacent and non-overlapping regions to compute the 1-D spatial autocorrelation function of each region; the autocorrelation function of an axon was calculated by averaging that of all segmented regions in the axon. The autocorrelation amplitude of an axon was defined as the difference in autocorrelation values between the local maximum around 190 nm and the local minimum around 95 nm in the average autocorrelation function curve of the axon.

The Occupancy ratio was defined as the βII spectrin occupancy over TuJ1-marked regions. Briefly, conventional wide-field images of βII spectrin and TuJ1 were binarized and morphological operation was performed on binarized TuJ1 images to remove boundary regions without breaking objects apart and convert axons into binary images of strokes. The strokes of axons were then registered with images of βII spectrin using an affine transform to correct for possible drift. βII spectrin signals outside of the TuJ1-marked regions were ignored. The occupancy ratio was calculated as the ratio of regions covered by βII spectrin signal over the TuJ1-marked regions.

Phosphorylation analysis {#s4-9}
------------------------

In brief, 620 µg protein per replicate (n = 3), in 110 µl of 8M Urea, were trypsinized and desalted. 20 µg of each digest was subjected to protein profiling while the remainder was subjected to titanium dioxide based phosphopeptide enrichment as described previously ([@bib12]). Samples were analyzed by high-resolution/high-accuracy LC-MS/MS (Q-Exactive Plus, ThermoFisher). LC setup was operated with a trap column. Tandem MS data were queried against Uniport's Mouse Complete Proteome (March 2016) using MaxQuant v. 1.6.0.13 ([@bib50]). Data were processed as a peptide centric stable isotope labeling by amino acids in cell culture experiment (Lysine +8 Da and Arginine +10 Da). Phosphorylation of Serine, Threonine and Tyrosine were allowed as variable modifications in addition to methionine oxidation and protein N-terminal acetylation. Only Peptide false discovery rate (1%) was used to filter matched peptides. Phosphorylation sites were considered if measured in 2-of-3 replicates and with a localization probability better than 0.75. Data were processed and analyzed using Perseus ([@bib51]). Phosphorylation sites were queried against PhosphoSite ([@bib19]). Measured phosphorylation sites of αII-spectrin, βII-spectrin, α-adducin, β−adducin and γ-adducin proteins are listed in [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"} and quantified in [Figure 2---figure supplement 2---source data 1](#fig2s2sdata1){ref-type="supplementary-material"}. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE ([@bib55]) partner repository with the dataset identifier PXD009854.

Statistical analysis {#s4-10}
--------------------

Statistical tests were performed using either MATLAB or Prism 7 (Prism). The statistical test applied to each quantification are indicated in each figure legend.
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Thank you for submitting your article \"Membrane cytoskeleton dynamics underlie the initiation of sensory axon degeneration\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Vann Bennett (Reviewer \#1)
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Summary:

Wang and colleagues report several interesting observations connecting the recently discovered axonal spectrin/actin rings with signaling leading to axon degeneration in cultured sensory neurons following removal of NGF (a surrogate for physiological axon pruning during development). The periodicity of the rings is disrupted within a few hours of NGF withdrawal well before onset of apoptosis and even when apoptosis is prevented altogether. Multiple sites of phosphorylation of αII and βII-spectrin and adducin that occur following NGF deprivation are described, although this is not followed up. The effects of manipulating spectrin/actin rings are examined by targeting actin with pharmacological agents and by knocking down βII-spectrin.

Essential revisions:

The paper represents a set of intriguing and generally well-executed experiments, however it does not add up to a coherent story. The results are strong but somewhat conflicting. Stabilizing actin prevents degeneration, but so does eliminating βII-βspectrin. A possible (likely) resolution is that both actin and β-spectrin have roles in addition to assembly of spectrin-actin rings. One issue is that the lack of in vivo data. The study is a bit thin on mechanistic insight on (i) how NGF withdrawal leads to rapid MPS disassembly, and (ii) how MPS remodeling promotes retrograde degenerative events including DLK and c-Jun activation. The paper could be strengthened by addressing the following essential points:

1\) Both actin and spectrin have pleiotropic roles that can complicate interpretation of inhibitors/knockdowns. A more precise target (such as a dedicated component of the spectrin/actin rings if one can be identified) could help. The authors should develop the unexpected finding that βII-spectrin elimination prevents/slows degeneration. Although inconvenient and difficult to explain in the short term, this could be the most interesting observation.

2\) One suggested experiment is to induce degeneration with LatA in neurons that lack β-spectrin, according to the authors model the axons should be protected, as the actin depolymerization will not be able to transmit the signal to the cell body.

3\) The authors provide evidence from a phosphoproteomic screen that MPS components may be phosphorylated following trophic deprivation and speculate that aberrant phosphorylation may lead to destabilization of MPS. Some direct evidence supporting this in sensory axons following TD would strengthen the study. Could the authors use phospho-deficient or phosphomimetic mutants of βII-spectrin to test their model? Furthermore, in a recent study (Unsain et al., 2018) that the authors cite, it was reported that NGF withdrawal results in a rapid 50% loss of βII-spectrin and actin in the MPS. Is this the case here? Does NGF withdrawal lead not only to aberrant phosphorylation but also a loss of MPS components? How can a rapid loss of MPS components following TD be reconciled with the proposed model here that MPS components are required to initiate axon degeneration?

4\) In the absence of a clear-cut mechanism, the authors should provide stronger support for the link between rapid MPS disassembly and DLK phosphorylation/stability/retrograde transport by including more rigorous analyses similar to that reported by Larhammar et al., 2017. For example, quantification of DLK abundance in βII-spectrin null neurons, evidence of retrograde transport of DLK/P-*JNK* to cell bodies in mutant neurons, quantification of p-c-Jun results for Figures 3 and 5 rather than just showing images. Similarly, for the DLK1 western blots shown in Figures 3 and 4 supplements, there is no information if this is from a single experiment or representative of multiple analyses. Moreover, DLK phosphorylation should be probed by a phospho-specific DLK antibody if available. These analyses are necessary to provide more convincing support for the notion that βII-spectrin, an essential component of MPS, is required for well-characterized degenerative signaling events during trophic deprivation.

5\) In the context of MPS disassembly initiating retrograde degenerative signaling, is the periodicity affected equally in all axonal segments after NGF withdrawal or does it show a specific pattern? Specifically, is there a progressive loss of periodicity from distal to proximal axon segments following NGF deprivation? It is not clear which regions of the axons were selected for imaging.

10.7554/eLife.38730.041

Author response

> Essential revisions:
>
> The paper represents a set of intriguing and generally well-executed experiments, however it does not add up to a coherent story. The results are strong but somewhat conflicting. Stabilizing actin prevents degeneration, but so does eliminating βII-spectrin. A possible (likely) resolution is that both actin and β-spectrin have roles in addition to assembly of spectrin-actin rings. One issue is that the lack of in vivo data. The study is a bit thin on mechanistic insight on (i) how NGF withdrawal leads to rapid MPS disassembly, and (ii) how MPS remodeling promotes retrograde degenerative events including DLK and c-Jun activation.

We thank the editor and reviewers for their constructive comments. Based on these comments, we have performed additional experiments and analyses and made text revisions, which have strengthened our manuscript.

Most of the comments in this general statement have been elaborated in the specific points below and hence we will address these comments in our response to the specific comments below. Here we only address the comment "One issue is that the lack of in vivo data" which has not been further mentioned below.

We agree that studying axon degeneration in vivo is an important goal. However, at any given time in vivo, of all axons, which travel in tight bundles of several hundred axons, only a small subset is degenerating, which has prevented us and other labs from having the spatial resolution to observe these few dying axons in the background of many more healthy ones. Indeed, we developed the whole-mount immunolabelling protocol iDISCO in part to attempt to visualize sensory axon degeneration in vivo, but have thus far been unable to visualize this process.

Hence, the use of cultured primary neurons to study the detailed molecular mechanisms of axon degeneration is the general practice in the field, particularly because, by initiating NGF deprivation at a fixed time we are able to see near-synchronous degeneration of axons. It is worth noting that we and others have extensively documented that the pathways of axon degeneration uncovered in vitro do indeed relate to the ultimate survival/death of these axons in vivo. For example, mouse mutants that delay (*Puma, DR6, APP, Puma*) or block (*Bax, Caspase-3*) axon degeneration display an increase in un-pruned axons in the visual system and an excess of sensory axons projecting to the periphery at later embryonic stages (Nikolaev et al., 2009; Simon et al., 2012, Olsen et al., J.Neurosci., 2014; Maor-Nof et al., 2016).

Finally, an additional challenge for this study is that super-resolution imaging in vivo has also been generally challenging. Moreover, the tight bundling of sensory axons in vivo (see above) would further hinder our ability to efficiently visualize the MPS and its disruption in the subset of axons that degenerate at any moment using super-resolution imaging.

> The paper could be strengthened by addressing the following essential points:
>
> 1\) Both actin and spectrin have pleiotropic roles that can complicate interpretation of inhibitors/knockdowns. A more precise target (such as a dedicated component of the spectrin/actin rings if one can be identified) could help. The authors should develop the unexpected finding that βII-spectrin elimination prevents/slows degeneration. Although inconvenient and difficult to explain in the short term, this could be the most interesting observation.

We agree with the reviewers that both actin and spectrin have pleiotropic roles that can complicate the interpretation of pharmacological actin manipulations or knockdown/knockout of βII spectrin. It would indeed be great to find more precise targets that only affect the MPS. To this end, we have made substantial effort trying to achieve this goal:

a\) We tried generating a mutant mouse where the actin-binding domain of βII spectrin can be conditionally deleted in culture using Cre-Lox recombination, with the hope of disrupting the MPS in more specific ways while still maintaining the presence of βII spectrin proteins and actin filaments. We tried this conditional knockout strategy because we are concerned that germline knockout would be lethal to the animal. However, even when we infected the culture neurons from this mutant mouse with a very high dose of Cre virus, only a fraction of βII spectrin had the actin-binding domain successfully deleted, as assayed by western blot. The problem of insufficient deletion could be either a result of low recombination rate for distantly spaced LoxP sites (the actin-binding domain encompasses 73 kb of genomic DNA) or due to the un-degraded full-length βII spectrin produced before the incidence of recombination. While we are exploring means to increase the recombination efficiency, these approaches require significantly more time than the scope of this revision. We plan to follow up on this in our future work.

b\) We also generated a germline knock-in mouse model with the K2207Q mutation in the PH domain of βII-spectrin which has been shown to abolish binding affinity of βII-spectrin for phosphoinositides in MDCK cells (He et al., J Cell Biol 2014 Jul 21; 206(2)). This mutant also has the benefit of maintaining the original length of βII-spectrin. Our logic was that, by abolishing the binding to phosphoinositides, we could potentially remove βII-spectrin from the plasma membrane and thus disrupt the MPS. However, we found that the MPS still persisted along axons, albeit with a discontinuous distribution containing gaps devoid of the MPS. We also did not observe protection against TD-induced degeneration in these cultures, not unexpectedly because the MPS is still present in axons.

c\) We observed TD-associated phosphorylation of MPS components, which could potentially facilitate dissociation of the MPS. Hence, it is possible that the MPS structure may be disrupted by engineering phospho-mimetic (S/T\>D) amino acids into the sequence of βII spectrin. We therefore generated a panel of S/T\>D (phospho-mimetic) and S/T\>A (phospho-deficient) mutations into a cDNA encoding the βII spectrin (*Sptbn1*) gene. However, *Sptbn1* cDNA is \~7.5kb long, far exceeding the maximum packaging sizes for both lentivirus and AAV, which has prevented us from successfully introducing these constructs to DRG neurons. We also made several attempts to introduce these mutations by cDNA transfection, each of which resulted in toxicity. Similar toxicity has been described for cDNA transfection in DRGs by other groups (Yu et al., Front Mol Neurosci. 2015 Feb 2;8:2.). In addition, we have explored adenovirus as a viral delivery system, which can typically package open reading frames up to \~6kb, and unfortunately these efforts also failed to express the full-length product of this cDNA in neurons.

Therefore, despite several months of effort, we were not able to generate mutants that can completely disentangle the role of the MPS from the role of other cytoskeletal structures or isolated βII spectrin. Therefore, even though the simplest explanation of our observed effects of actin and spectrin manipulations converge on the MPS, we revised the Discussion section of the manuscript to explicitly acknowledge that other cytoskeleton structures or other roles of actin and spectrin outside the MPS may also contribute to the observed effects of actin manipulations and spectrin perturbation on axon degeneration (see subsection "Structural plasticity of the MPS potentially functions to initiate retrograde signaling", last paragraph).

We also agree with the reviewers that it would be interesting to develop the unexpected finding that βII spectrin elimination prevents/slows degeneration. Following the reviewer's suggestion, we have performed additional experiments on retrograde signaling induced by TD in βII spectrin knockdown neurons to show that the loss-of-βII spectrin acts downstream of the activation of DLK kinase but upstream of the activation of the transcription factor c-Jun (see subsection "Depletion of MPS component βII spectrin protects axons from degeneration", first paragraph and Figure 5, Figure 5---figure supplement 1). We have also performed additional experiments on LatA-induced axon degeneration in βII spectrin knockdown neurons to show that βII spectrin depletion also protect axons from degeneration under LatA treatment by measuring the Caspase3-like enzymatic activity ('DEVDase') in axons (see subsection "Depletion of the MPS component βII spectrin protects axons from degeneration", last paragraph; Figure 5---figure supplement 3). Finally, we elaborated the implication of the finding that βII spectrin depletion protect axons from degeneration by providing two possible models to explain this result: 1) It is possible that the MPS sequesters pro-degenerative signaling molecules in healthy axons to prevent aberrant signaling, but also primes axons for degeneration by recruiting these molecules to the appropriate region of the axons. MPS disassembly might then activate the retrograde signaling by releasing these signaling molecules. On the other hand, inhibition of the formation of the MPS by βII spectrin depletion could lead to mis-localization of these signaling molecules, resulting in failure of retrograde signaling. 2) Another possibility is that MPS breakdown during TD (or following LatA treatment) produces a pool of soluble MPS components, such as spectrin and ankyrin, which could participate in retrograde trafficking of pro-degenerative signals. Both spectrin and ankyrin B have been shown to interact with motor proteins that move on microtubules. The disassembly of the MPS to free these MPS components could promote the role of these proteins in retrograde transport, which may in turn facilitate retrograde signaling in TD induced axon degeneration. Please see subsection "Structural plasticity of the MPS potentially functions to initiate retrograde signaling", second paragraph for these discussions.

> 2\) One suggested experiment is to induce degeneration with LatA in neurons that lack β-spectrin, according to the authors model the axons should be protected, as the actin depolymerization will not be able to transmit the signal to the cell body.

We thank the reviewers for suggesting this informative experiment. We have performed this additional experiment and added the results to the revised manuscript. As suggested by the reviewer, our model predicts that βII spectrin deletion will protect axon from degeneration induced by LatA. This is indeed what we observed. We elaborate this finding below:

In our original manuscript we showed that application of LatA led to activation of axonal Caspase-3 and that axonal Caspase-3 activation does not occur when LatA is added to isolated axons that have been severed from their cell bodies (Figure 3E). These results indicate that acute breakdown of F-actin in the axon generates a retrograde signal to the cell body, followed by an anterograde signal from the cell body to the axon that activates axonal Caspase-3, similar to the mechanism by which TD activates axonal Caspase-3.

As suggested by the reviewers, we now performed new experiments to study whether LatA treatment still induces axon degeneration in βII spectrin knockdown neurons. Our new results showed that βII spectrin knockdown indeed prevented increase in axonal Caspase-3-like enzymatic activity in this case, similar to the case of TD-induced axon degeneration (see subsection "Depletion of the MPS component βII spectrin protects axons from degeneration", last paragraph, Figure 5---figure supplement 3A). We note that βII spectrin knockdown did not prevent c-Jun activation in the case of LatA treatment (see the aforementioned paragraph, Figure 5---figure supplement 3B, C), even though TD-induced c-Jun activation was prevented by βII spectrin knockdown. This is likely because LatA treatment, which disrupts all forms of F-actin, initiates additional, less specific and βII spectrin-independent signal to activate c-Jun, which does not occur during TD. Nevertheless, the observation that βII spectrin knockdown blocks both LatA-induced and TD-induced axonal Caspase-3-like enzymatic activity indicates that βII spectrin is critical to retrograde signaling on the TD-induced (and related LatA-induced) axon degeneration pathway.

> 3\) The authors provide evidence from a phosphoproteomic screen that MPS components may be phosphorylated following trophic deprivation and speculate that aberrant phosphorylation may lead to destabilization of MPS. Some direct evidence supporting this in sensory axons following TD would strengthen the study. Could the authors use phospho-deficient or phosphomimetic mutants of βII-spectrin to test their model?

We agree that it would be very interesting to obtain direct evidence supporting the hypothesis that TD-induced phosphorylation of MPS component may lead to destabilization of MPS. We have made several attempts to address this issue by generating both phospho-deficient (S/T\>A) and phospho-mimetic (S/T \> D) mutation variants of βII spectrin. However, the βII spectrin (*Sptbn1*) gene, which is \~7.5kb long, far exceeds the maximum packaging sizes for both lentivirus and AAV, which has prevented us from successfully introducing these constructs to DRG neurons. We made several attempts on introducing these mutations by cDNA transfection, each of which resulted in toxicity. Similar toxicity has been described for cDNA transfection in DRGs by other groups (Yu et al., Front Mol Neurosci. 2015 Feb 2;8:2.). In addition, we have explored adenovirus as a viral delivery system, which can typically package open reading frames up to \~6kb. Unfortunately, these efforts also failed to express the full-length product of this cDNA in neurons. We therefore were not able to perform this suggested experiment despite several months of effort. Because we have not been able to address the functional role for these phosphorylations, we have further softened our discussion regarding their relevance to MPS disruption and axon degeneration (see subsection "The early disassembly of MPS is independent of apoptotic pathway activation and protein loss", last paragraph and subsection "Depletion of βII-spectrin inhibits retrograde signaling and protects axons from degeneration"). Despite this, we feel that the inclusion of the identification of these sites has value and will be of great interest to labs that are exploring the biology of the MPS.

> Furthermore, in a recent study (Unsain et al., 2018) that the authors cite, it was reported that NGF withdrawal results in a rapid 50% loss of βII-spectrin and actin in the MPS. Is this the case here? Does NGF withdrawal lead not only to aberrant phosphorylation but also a loss of MPS components? How can a rapid loss of MPS components following TD be reconciled with the proposed model here that MPS components are required to initiate axon degeneration?

We note that (Unsain et al., 2018) did not probe the abundance of βII-spectrin, actin or other MPS components. Instead, Unsain et al. reported the so-called MPS abundance, which is defined as the fraction of axonal regions that exhibited periodic distribution of βII-spectrin or actin. Hence, this study only concluded that the MPS structure is disrupted upon NGF withdraw, but did not conclude on any loss of βII-spectrin, actin or other MPS components.

In our manuscript, we showed that the MPS disassembly upon TD occurs early and prior to the activation of the apoptotic activity and that the TD-induced MPS disassembly still occurs in axons where the apoptotic pathway is blocked. These results suggest that the observed MPS disassembly is unlikely a result of the reduced abundance of MPS components.

However, in light of this reviewer comment, we performed additional experiments to probe whether there is a decrease in abundance of the MPS molecular components upon TD.

a\) We measured the total abundance of βII spectrin in axons, reflected by the average fluorescence intensity, and found that the βII spectrin remains unchanged during the entire 12 h observation period after TD (Figure 2---figure supplement 1), whereas MPS disassembly has already occurred substantially before the 12 h time point (MPS is substantially disrupted already by 3-6 h time after TD, see Figure 1, 2).

b\) We extended our analysis to test whether other MPS components are lost during the relevant window of TD. Towards this end, we performed a series of Western Blots on axonal proteins to examine the abundance of MPS components, αII spectrin, βII spectrin, and actin, during a time course of TD.

Our key observations (Figure 2B) are:

i\) Total protein abundance of βII spectrin and actin remained constant during the entire 18hr assay window.

ii\) Proteolysis of αII spectrin did occur during TD, but only beginning at the 12hr time point and in a Caspase-dependent manner.

In sum, the behavior of the MPS that we observed is not a consequence of reduced abundance of MPS component proteins. These data additionally contribute towards our hypothesis that MPS disassembly potentially has an upstream role during axon degeneration.

> 4\) In the absence of a clear-cut mechanism, the authors should provide stronger support for the link between rapid MPS disassembly and DLK phosphorylation/stability/retrograde transport by including more rigorous analyses similar to that reported by Larhammar et al., 2017. For example, quantification of DLK abundance in βII-spectrin null neurons, evidence of retrograde transport of DLK/P-JNK to cell bodies in mutant neurons, quantification of p-c-Jun results for Figures 3 and 5 rather than just showing images. Similarly, for the DLK1 western blots shown in Figures 3 and 4 supplements, there is no information if this is from a single experiment or representative of multiple analyses. Moreover, DLK phosphorylation should be probed by a phospho-specific DLK antibody if available. These analyses are necessary to provide more convincing support for the notion that βII-spectrin, an essential component of MPS, is required for well-characterized degenerative signaling events during trophic deprivation.

As suggested, we performed additional experiments to examine the DLK abundance in βII spectrin null axons and found that it was not appreciably different than that in WT axons (See Figure 5I). Interestingly, although loss of βII spectrin protected axons from degeneration and inhibited the activation of c-Jun, it did not block DLK activation (assayed by the phosphorylation-dependent shift in DLK molecular weight) (Figure 5I), suggesting that βII spectrin likely functions downstream of DLK activation but upstream of c-Jun.

Also as suggested by the reviewer, we have added quantification of the magnitude of c-Jun phosphorylation in Figures 3 and 5 to show more clearly the c-Jun activation in TD cultures and LatA treated cultures and the reduction in c-Jun activation with DLK inhibition and βII spectrin depletion. In addition to quantifying phosphorylated c-Jun, we also added an additional assay to quantify increase in c-Jun mRNA abundance induced by TD. This induction is also largely blocked by βII spectrin knockdown (Figure 5---figure supplement 1D).

We thank the reviewers for the suggestion to include information about our sample size. We have updated our figure legends of Figure 3 and Figure 4 supplements (Figure 3---figure supplement 1 and Figure 4---figure supplement 2) to include the number of DLK1 western blot experiments performed for each representative figure shown (3 independent experiments).

Regarding the reviewer's comment about detection of DLK activation: DLK is activated by phosphorylation near its active site and unfortunately no phospho-specific antibodies to these sites have been published or are commercially available. There are phosphospecific antibodies to phosphorylation sites outside of the activation site that work in 293T cells (Huntwork-Rodriguez et al., 2013), but we have been unable to obtain a convincing signal in our axonal samples using these antibodies. Nevertheless, the molecular weight shift that we employed is both widely used and well-validated as a DLK activation assay in the previous studies (Watkins et al., 2013; Huntwork-Rodriguez et al., 2013; Larhammar et al., 2017; Larhammar et al., J.Neurosci., 2017), and therefore we are confident in its use as a surrogate for DLK activation.

> 5\) In the context of MPS disassembly initiating retrograde degenerative signaling, is the periodicity affected equally in all axonal segments after NGF withdrawal or does it show a specific pattern? Specifically, is there a progressive loss of periodicity from distal to proximal axon segments following NGF deprivation? It is not clear which regions of the axons were selected for imaging.

We apologize for not making this clear in our manuscript. Our results here focus on the distal axons. In light of this reviewer comment, we have performed additional experiments to image the proximal axon segments adjacent to the cell body, but interestingly, the MPS is not as well formed (i.e. βII spectrin exhibits relatively poor periodicity) in the axon region proximal to the cell body of DRG neurons even in the presence of NGF (Figure 1---figure supplement 2). We have now included this result in the revised manuscript. In the distal axons, without the presence of the cell body in the same field of view, it is difficult to determine which end of the axon segment is closer to the cell body. In general, the density of the axons makes it challenging to trace the axons all the way back to the cell body to determine orientation of the axon segments, which prevents us from making a conclusion on whether the disruption of the MPS propagates from distal to proximal axon segments.

[^1]: Department of Biochemistry, Weill Cornell Medical College, New York, United States.
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